A. Doherty

J. Mcculloch, A. Doherty, D. Graham, 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Novel selective quinazoline inhibitors of endothelin converting enzyme-1.

S. B. Herman, A. Doherty, D. Hupe, 1998, Biochemical and biophysical research communications.

In vitro and in vivo studies with a series of hexapeptide endothelin antagonists.

A. Doherty, W. L. Cody, E. Reynolds, 1993, Journal of cardiovascular pharmacology.

Importance of secondary structure for endothelin binding and functional activity.

A. Doherty, J. Dunbar, R. Panek, 1992, Biochemical and biophysical research communications.

[125I]‐PD 151242: a selective radioligand for human ETA receptors

A. Doherty, A. Davenport, J. Maguire, 1994, British journal of pharmacology.

Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.

A. Doherty, M. J. Ryan, M. Taylor, 1992, Journal of medicinal chemistry.

Effects of selective endothelin antagonists on the hemodynamic response to cyclosporin A.

A. Doherty, J. Keiser, W. L. Cody, 1994, Journal of the American Society of Nephrology : JASN.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

W. Denny, A. Doherty, A. Bridges, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Syntheis of TRP-VAL non-cleavable dipeptide transition state isosteres

A. Doherty, B. Kornberg, 1993 .

Plasma-levels of endothelin-1 and angiotensin-II and reactivity of arterial blood pressure to exogenous sympathomimetics and vasoactive peptides in rat model of malignant renal hypertension.

A. Doherty, V. Kettmann, J. Dřímal, 2000, Bratislavske lekarske listy.

Structure-activity relationships of C-terminal endothelin hexapeptide antagonists.

A. Doherty, D. T. Dudley, W. L. Cody, 1993, Journal of medicinal chemistry.

Monocyclic endothelins: examination of the importance of the individual disulfide rings.

A. Doherty, R. Panek, T. Major, 1991, Journal of cardiovascular pharmacology.

An efficient strategy for the large-scale synthesis of head-to-tail cyclic peptides

A. Doherty, W. L. Cody, J. He, 1994, Letters in Peptide Science.

Synthesis of novel substituted pyridines as inhibitors of endothelin converting enzyme-1 (ECE-1).

S. B. Herman, A. Doherty, K. Ahn, 1998, Bioorganic & medicinal chemistry letters.

Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors

A. Doherty, W. L. Cody, E. Reynolds, 1995 .

The design of potent hexapeptide endothelin antagonists stable to proteolysis

A. Doherty, B. H. Stewart, E. Reyner, 1995 .

Antagonism of renal and systemic responses to endothelin-1 infusion with PD 145065.

J. Vane, A. Doherty, R. Corder, 1994, European journal of pharmacology.

Structure-activity relationships in a series of monocyclic endothelin analogues

A. Doherty, D. T. Dudley, W. L. Cody, 1994 .

Structure-activity and modeling studies of tryptophan-modified peptidyl antagonists of endothelin

A. Doherty, J. Dunbar, T. Sawyer, 1994 .

Treatments for myocardial ischaemia

A. Doherty, 1994 .

Structure-activity relationships in the C-terminus of endothelin-1 (ET-1): The discovery of potent antagonists

J. Topliss, A. Doherty, W. L. Cody, 1993 .

Endothelin and structurally related analogs distinguish between endothelin receptor subtypes.

A. Doherty, R. Panek, T. Major, 1992, Biochemical and biophysical research communications.

Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat

A. Eschalier, D. Ardid, A. Doherty, 2006, Gut.

Therapeutic Potential of Endothelin Receptor Antagonists in Experimental Stroke

D. Graham, J. Mcculloch, A. Doherty, 1995, Journal of cardiovascular pharmacology.

Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase.

A. Doherty, J. Sebolt-Leopold, J. C. Hodges, 1997, Journal of medicinal chemistry.

Cardiac effects of endothelin-1 (ET-1) and related C terminal peptide fragment: increased inotropy or contribution to heart failure?

A. Doherty, V. Kettmann, J. Dřímal, 2003, Physiological research.

Design and synthesis of renin inhibitors: incorporation of transition-state isostere side chains that span from the S1 to the S3 binding pockets and examination of P3-modified renin inhibitors.

C. Humblet, E. Lunney, A. Doherty, 1995, Journal of medicinal chemistry.

Potent and selective bicyclic lactam inhibitors of thrombin: Part 3: P1' modifications.

D. R. Holland, J. DiMaio, A. Doherty, 1999, Bioorganic & medicinal chemistry letters.

Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications.

D. R. Holland, J. DiMaio, A. Doherty, 1998, Bioorganic & medicinal chemistry letters.

Potent bicyclic lactam inhibitors of thrombin: Part I: P3 modifications.

J. DiMaio, A. Doherty, J. Rubin, 1998, Bioorganic & medicinal chemistry letters.

Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors.

A. Doherty, H. W. Hamilton, B. Steinbaugh, 1992, Journal of medicinal chemistry.

Natural Products Chemistry

A. Doherty, L. Paquette, 1987 .

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.

Endothelin receptor antagonists: synthesis and structure-activity relationships of substituted benzothiazine-1,1-dioxides.

A. Doherty, J. Bryant, J. Edmunds, 1998, Bioorganic & medicinal chemistry.

Total synthesis of furanocembranolides. 1. Stereocontrolled preparation of key heterocyclic building blocks and assembly of a complete seco-pseudopterane framework

A. Doherty, C. Rayner, L. Paquette, 1992 .

Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists.

A. Doherty, A M Doherty, W C Patt, 1995, Journal of medicinal chemistry.

The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: part 1.

A. Doherty, J. Rubin, P. Winocour, 1999, Bioorganic & medicinal chemistry letters.

Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.

A. Doherty, J. Keiser, H. Hallak, 1997, Journal of medicinal chemistry.

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

A. Doherty, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

A. Doherty, D. W. Fry, J. M. Hamby, 1997 .

A study of the 3,3-sigmatropic rearrangement of chiral trichloroacetamidic esters

A. Doherty, M. Reily, B. Kornberg, 1993 .

Patent Update Cardiovascular & Renal: Treatments for myocardial ischaemia

A. Doherty, 1994 .

New inhibitors of human renin that contain novel replacements at the P2 site.

A. Doherty, M. Taylor, J. C. Hodges, 1991, Journal of medicinal chemistry.

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.

A. Doherty, H. D. Showalter, J. M. Hamby, 2001, Journal of medicinal chemistry.

Preparation of 2-substituted pyrroles and indoles by regioselective alkylation and deprotection of 1-(2-trimethylsilylethoxymethyl)pyrrole and 1-(2-trimethylsilylethoxymethyl) indole

A. Doherty, M. Edwards, S. Ley, 1986 .

Polyquinane Chemistry: Syntheses and Reactions

A. Doherty, L. Paquette, 1987 .

Synthesis of hydroxamic acids: PdBaSO4 as a new catalyst for the deprotection of O-benzyl hydroxamates

A. Doherty, Donald R. Johnson, S. Nikam, 1995 .

Total Synthesis of Furanocembranolides. Part 1. Stereocontrolled Preparation of Key Heterocyclic Building Blocks and Assembly of a Complete seco-Pseudopterane Framework.

A. Doherty, C. Rayner, L. Paquette, 1992 .

Synthesis of spiroacetals using organoselenium-mediated cyclisation reactions. X-Ray molecular structure of (2S,8R)-8-methyl-2-phenyl-1,7-dioxaspiro[5.5]undecan-4(R)-ol

David J. Williams, A. Doherty, S. Ley, 1984 .

Large-scale production of a therapeutic protein in transgenic tobacco plants: effect of subcellular targeting on quality of a recombinant dog gastric lipase

S. Dufour, A. Doherty, P. Berna, 2001, Molecular Breeding.

Discovery and development of an endothelin A receptor-selective antagonist PD 156707.

A. Doherty, A. Uprichard, 1998, Pharmaceutical biotechnology.

Design and discovery of nonpeptide endothelin antagonists

A. Doherty, 1996 .

The development of potent peptide agonists and antagonists for the endothelin receptors

A. Doherty, W. L. Cody, 1995, Biopolymers.

Kinetics of oxidation of nitrogen compounds by cerium(IV)

A. Doherty, G. Stedman, M. D. Radcliffe, 1999 .

Design of a functional hexapeptide antagonist of endothelin.

A. Doherty, R. Panek, T. Major, 1992, Journal of medicinal chemistry.

Structure-activity and biophysical studies of the C-terminal hexapeptide of endothelin

A. Doherty, J. Dunbar, M. Reily, 1995 .

Endothelin antagonists: The rational design of combined and ETB receptor subtype selective antagonists

A. Doherty, W. L. Cody, E. Reynolds, 1994 .

In vitro stability and intestinal absorption characteristics of hexapeptide endothelin receptor antagonists.

G. Amidon, A. Doherty, B. H. Stewart, 1998, Life sciences.

In vitro assessment of oral delivery for hexapeptide endothelin antagonists.

A. Doherty, B. H. Stewart, E. Reyner, 1996, Life sciences.

Endothelin receptor antagonists: actions and rationale for their development.

A. Doherty, T. Warner, B. Battistini, 1994, Biochemical pharmacology.

Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat.

A. Doherty, F. Raymond, L. Diop, 2002, The Journal of pharmacology and experimental therapeutics.

C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.

A. Doherty, D. Mcnamara, E. Dobrusin, 1997, Journal of medicinal chemistry.

Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties.

A. Doherty, M. Reily, B. H. Stewart, 1997, Journal of medicinal chemistry.

In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.

A. Doherty, J. M. Hamby, R. Panek, 1997, The Journal of pharmacology and experimental therapeutics.

Kinetics and mechanism of the reaction of nitrous acid with 2,4-dinitrophenylhydrazine

A. Doherty, Á. Dobos, G. Stedman, 1996 .

Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity.

D. R. Holland, A. Doherty, R. Panek, 1998, Journal of medicinal chemistry.

Visible spectrum of dinitrogen trioxide in aqueous solution

A. Doherty, G. Stedman, E. Jones, 1996 .

Structure-activity studies of phosphorylated peptide inhibitors of the association of phosphatidylinositol 3-kinase with PDGF-β receptor

A. Doherty, R. Panek, G. Lu, 1995 .

Signalling approaches to inhibition of cellular proliferation

A. Doherty, D. Mcnamara, R. Panek, 2002 .

2-Substituted Aminopyrido[2,3- d ]pyrimidin-7(8 H )-ones. Structure−Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity

D. Boschelli, A. Doherty, H. D. Showalter, 1998 .

Design of C-terminal peptide antagonists of endothelin: structure-activity relationships of ET-[16–21, D-His16]

A. Doherty, J. Dunbar, W. L. Cody, 1993 .

An efficient preparation of the potent and selective pseudopeptide thrombin inhibitor, inogatran

A. Doherty, W. L. Cody, M. A. Siddiqui, 1997 .

An Efficient Preparation of the Potent and Selective Pseudopeptide Thrombin Inhibitor Inogatran.

A. Doherty, W. L. Cody, M. A. Siddiqui, 1997 .

Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor.

A. Doherty, R. Panek, G. Lu, 1997, Life sciences.

Endbtheein Structure and Development of Receptor Antagonists

A. Doherty, 2020, CHEMICAL and STRUCTURAL APPROACHES to RATIONAL DRUG DESIGN.

Butenolide endothelin antagonists with improved aqueous solubility.

J W Bryant, A. Doherty, J. Keiser, 1999, Journal of medicinal chemistry.

The solution structure of a cyclic endothelin antagonist, BQ‐123, based on 1H–1H and 13H–1H three bond oupling constants

A. Doherty, J. Dunbar, Michael D. Reily, 1992, FEBS letters.

Structure-activity studies of the C-terminal region of the endothelins and the sarafotoxins.

A. Doherty, R. Panek, T. Major, 1991, Journal of cardiovascular pharmacology.

Synthetic studies towards the acyltetronic acid iohophore M 139603

A. Doherty, S. Ley, 1986 .

Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.

E. Hennessy, Nichola L. Davies, A. Doherty, 2021, Journal of medicinal chemistry.

The reactivity of dinitrogen trioxide and of nitrosyl thiocyanate

A. Doherty, M. Garley, G. Stedman, 1986 .